Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period

Inclusion Criteria: * Patients 18 years of age or older * Patients affiliated to a social security or equivalent regimen * Patients agreeing to participate in the study (Patient with signed informed consent ) * Patients with evidence of myocardial ischemia (stable or unstable angina, silent ischemia, positive functional exploration or a reversible modification in the ECG consistent with ischemia). * Patient acceptable candidate for CABG surgery * Patient agreeing to undergo all protocol scheduled follow-up examinations. * Patients who tolerate the association Aspirin (dosed 75 to 160 mg/day) and Clopidogrel at 75 mg/day for at least 6 months Angiographic inclusion criteria: * Patient with de novo and sole in-stent restenosis (focal, diffuse or proliferative) in a non-coated metallic stent with or without any other coronary lesions. * Patient with target reference vessel diameter between 2.5 and 4 mm by visual estimate * Patient with a target lesion ≤ 22mm by visual estimate * Patient with a target lesion in an artery with a visual estimate of the restenosis between 50 and 99% and a TIMI flow grade \> 1 * Patient with multiple lesions, the other lesions have been treated with success Exclusion Criteria: * Patient in emergency * Patient pregnant * Patient nursing * Patient unable to give informed consent personally. * Patient with myocardial infarction within the previous 72 hours. * Patient with limited life expectancy (lesser than 1 year post-inclusion) * Patient with unstable arrhythmia * Patient with left ventricular ejection fraction (LVEF) lesser than 30% * Patient receiver of a cardiac or any other organ transplantation or candidate to an organ transplant * Patient who receive or scheduled to receive chemo- or radio- therapy within the 30 days prior to any protocol-related procedure. * Patient treated with immunosuppressives or for known immunodepressive or auto-immune pathologies * Patient receiving chronically anticoagulant therapy with an INR greater than 2.5 * Patient with known hypersensitivity or contraindications to anti-platelet drugs, everolimus, heparin, chromium cobalt alloys, nickel, tungsten, acrylic- or fluoro- polymers or sensitivity to angiographic contrast agents. * Patient with planned elective surgery requiring the interruption or discontinuation of anti-platelet therapy. * Patient with platelet count \<100 000/ mm3 or \>700 000mm3 ; WBC counts \<3 000/mm3 or known or suspected liver disease * Patient with severe renal insufficiency (creatinine clearance rate \< 30 ml/min), or under dialysis * Patient with an history of coagulopathy refusing blood transfusion * Patient who had a stroke/cerebrovascular accident or transient cerebrovascular ischemia in the preceding 6 months * Patient with urinary or gastro-intestinal bleed in the preceding 6 months * Patient with other known serious medical illness or known history of substance abuse (alcohol, drugs) that might result in non-compliance to the investigational plan, or interfere with the results or diminish the life expectancy to less than a year. * Patient enrolled in an interventional study with another medical device or drug Angiographic exclusion criteria * Patient with in-stent restenosis located on the left main on the coronary by-pass * Patient with a lesion of the in-stent restenosis located in a bifurcation including a lateral branch of diameter \> 1.5mm * Patient with the target vessel totally occluded * Patient with a lesion of the restenosis previously treated with another device (with the exception of balloon-tipped catheter) such as a cutting balloon, an atherectomy, laser, brachytherapy or any another medicated stent. * Patient with thrombus in the target vessel * Patient with aorto-ostiale lesions * Patient with previous failures of multiple lesions treated by angioplasty.